Recently approved recombinant factor VIII (rFVIII) for the replacement treatment in patients with hemophilia A in Italy by Roggeri, Daniela Paola et al.
55© 2017 The Authors. Published by SEEd srl. This is an open access article under the CC BY-NC 4.0 license (https://creativecommons.org/licenses/by-nc/4.0)
Keywords
Hemophilia A, Recombinant factor VIII, Dosage, Number of administration
Recently approved recombinant 
factor VIII (rFVIII) for the 
replacement treatment in patients 
with hemophilia A in Italy
Daniela Paola Roggeri 1, Ezio Zanon 2, Alessandro Roggeri 1
1 ProCure Solutions, Nembro (BG), Italy
2 Regional Center for prevention, prophylaxis and advanced treatment of hemophilic arthropathy. Hemophilia Center, University 
Hospital of Padua, Italy 
HemopHilia a
Inherited or acquired genetic mutation re-
sulting in dysfunction or deficiency of factor 
VIII (FVIII) or acquired inhibitor that binds 
FVIII are causes of Hemophilia A, a rare 
bleeding disorder. Among patients with ge-
netic Hemophilia A, up to one third of cases 
are the results of new mutations (not present 
in the mother’s X chromosome) [1].
Dysfunction or deficiency of FVIII leads to 
an insufficient generation of thrombin by the 
FIXa and FVIIIa complex by means of the 
intrinsic pathway of the coagulation cascade. 
This mechanism, in combination with the 
effect of the tissue-factor pathway inhibitor, 
generates, depending on the level of FVIII 
activity, a relevant trend towards easy bru-
ising or inadequate clotting of traumatic or 
even mild injury or, particularly in subjects 
with severe hemophilia, with spontaneous 
hemorrhage [1].
Hemophilia A is classified as mild, modera-
te, or severe depending on the amount of the 
clotting FVIII in blood. In severe hemophilia 
A, the FVIII levels are practically undetecta-
ble (<1%) causing chronic debilitating joint 
disease results from repeated hemarthrosis, 
synovial membrane inflammation, hypertro-
phy and, in some cases, destructive arthritis. 
In order to prevent functional disability, early 
replacement of coagulation factors throu-
gh infusion is necessary. In most developed 
countries, the standard of care is the prophy-
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In Italy, from the epidemiological point of 
view, the National Register of Congenital 
Coagulation Disorders [2] reported in 2014 a 
prevalence of the disease of 6.4 per 100,000 
inhabitants, it substantially confirms the fin-
dings of the “World Federation of Hemophi-
lia”; of the 3,906 registered subjects with he-
mophilia A, 1,800 had the severe form.
Hemophilia A has a significant impact on pa-
tients’ quality of life (school, work, private 
life) and [3,4] to date has no cure. Moreo-
ver, increased disability and quality of life 
impairment increase with increased age, hi-
gher reported bleed frequency and lower em-
ployment [4].
management of patients 
witH HemopHilia a
As stated in both the international guideli-
nes (World Federation of Hemophilia) and 
the Italian guidelines (Associazione Italiana 
Centri Emofilia), the treatment for patients 
with hemophilia A consists in the intrave-
nous administration of the deficient or absent 
factor (FVIII) [5,6]. At the moment two stra-
tegies are availabe: on demand treatment, 
consisting in the treatment of an ongoing he-
morrhage by infusing FVIII (which allows a 
temporary correction of the FVIII deficiency) 
or prophylaxis (long-term, regular infusion 
of FVIII), which reduce the bleeding ten-
dency, and, consequently, the negative con-
sequences of the hemorrhages on the joints, 
maintaining the factor levels in circulation 
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potential non-capsulated viruses, previously 
unknown pathogens and protein aggregates, 
thus reducing the risk of pathogen transmis-
sion.
The efficacy and safety of Kovaltry® were 
assessed in the LEOPOLD broad clinical de-
velopment programme [9-11] that consisted 
of three international trials conducted on over 
200 children, adolescents and adults with he-
mophilia A.
The use of Kovaltry® in prophylaxis demon-
strated a decrease in the annualised bleeding 
rate (ABR) of about 97%, compared to the 
on-demand treatment (2 vs. 60 bleeds/patient/
year; p < 0.0001) allowing the progression of 
the hemophilic arthropathy to be reduced [9].
The LEOPOLD I and LEOPOLD II trials 
also demonstrated that Kovaltry® allows ef-
fective prevention of bleeds both with 3 in-
fusions per week (3x) and with 2 infusions 
per week (2x). In LEOPOLD I trial, 29% of 
patients received the prophylaxis regime with 
administration twice a week, while in LEO-
POLD II trial 47% was randomized to recei-
ve this reduced prophylaxis regime. Moreo-
ver, about 30% of the patients in prophylaxis 
with Kovaltry® reported no bleeds during the 
observation period. In the LEOPOLD Kids 
Part A trial, 45,1% patients had no bleeds du-
ring the six months treatment period [11].
Regarding the immunogenicity, in Kovaltry® 
clinical trials conducted on more than 200 
patients (children and adults) with severe he-
mophilia A (FVIII < 1%) and previously tre-
ated with FVIII ≥ 50 ED, no inhibitors were 
detected.
elocta®
Elocta® (efmoroctocog alfa, Swedish Orphan 
Biovitrum srl) a recombinant human coagula-
tion factor VIII, Fc fusion protein (rFVIIIFc), 
has 1890 amino acids. It is produced by re-
combinant DNA technology in a human em-
bryonic kidney cell line (HEK) without the 
addition of any exogenous human or animal-
derived protein in the cell culture process, 
purification or final formulation [12].
The safety, efficacy, and pharmacokinetics 
of Elocta® was evaluated in 2 multinational, 
open-label, pivotal studies [13,14]; median 
annualized bleeding rates estimates from a 
negative binomial regression model were 
2.91 (the ABR was estimated using the ne-
gative binomial model) for subjects in the 
individualized prophylaxis arm, 8.92 for 
subjects in the weekly prophylaxis arm and 
37.25 for subjects in the on demand treatment 
arm. No bleeding episodes were experienced 
in 45.3% of subjects while on individualized 
prophylaxis and in 17.4% of subjects while 
on weekly prophylaxis.
and avoiding spontaneous bleeds [5,6]. The 
administration of FVIII, which in the past 
was carried out in hospital setting, is curren-
tly carried out (after adequate training of the 
patient or caregivers) at home also thanks to 
the availability of biotechnologic drugs, lea-
ding to an improvement in the quality of life 
of the patients themselves and their families 
[7].
The approach currently recognised as the 
most suitable treatment for the prevention 
of joint complications is the prophylaxis, to 
be started early in children with severe he-
mophilia A; the benefits of such a treatment 
regime have also been demonstrated in ado-
lescent and adult patients. Prophylaxis usual-
ly requires the administration of factor three 
times a week, or on alternate days, although 
the frequency of administration can vary, 
depending on the type of drug used and the 
response of the individual patient to that drug 
(pharmacokinetics) the bleeding phenotype 
and the patient’s daily activities and life style.
Since 90’s, the available treatments have 
improved in safety, with the use of plasma 
concentrations produced through increasin-
gly sophisticated purification techniques, 
which undergo viral inactivation, to factors 
obtained with recombinant DNA technology, 
which have no protein of human or animal 
origin.
As recently in Italy three new drugs have 
been made available for the treatment and 
prophylaxis of bleeding in patients with 
hemophilia A, our aim is to compare drugs 
consumption for all the recombinant FVIII 
actually reimbursed by the Italian National 
Health Service (NHS).
Kovaltry®
Kovaltry® (octocog alfa, Bayer SpA) a full 
length recombinant human coagulation fac-
tor VIII (rDNA), is a purified protein that has 
2332 amino acids; it is produced by recombi-
nant DNA technology in baby hamster kidney 
cells (BHK) into which the human factor VIII 
gene has been introduced [8]. The new manu-
facturing advances allow the co-expression 
of the human chaperone protein heat shock 
protein 70 (HSP70); HSP70 is a chaperone 
protein that may increase FVIII expression 
by facilitating proper protein folding and im-
proves cell survival by inhibiting apoptosis 
(i.e., programmed cell death). Kovaltry® is 
prepared without the addition of any human 
or animal derived protein in the cell culture 
process, purification or final formulation and 
has undergone nanofiltration with a 20 nm 
filter. The addition of this method to the pro-
duction process represents a further guaran-
tee of safety, since it is able to remove even 
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re Inc.), Refacto AF® (moroctocog alfa from 
CHO protein free, Pfizer S.r.l.), NovoEight® 
(turoctocog alfa from CHO protein free, 
Novo Nordisk S.p.A.) and Nuwiq® (simoc-
tocog alfa from HEK protein free, Octaphar-
ma Italy S.p.A.). For each of these drugs, the 
summary of product characteristics recom-
mends a dosage of 20-40 IU/kg every 2/3 
days [12,15,18-24] except for NovoEight® 
(turoctocog), which is recommended at a do-
sage of 20-40 IU/kg every two days or 20-
50IU/kg 3 times a week [25].
Comparison between 
available treatments
Table I reports the annual average con-
sumption per patient (dosage X number of 
administrations) of the available treatments 
based on  European SPCs [12,15,18-25].
Data from clinical trials reported that for Ko-
valtry® the 30% of patients were treated with 
two administrations per week and for Elocta® 
this percentage account at 33%.
Even though the average number of admini-
strations per years appears to be lower with 
Elocta®, if we consider the total consumption 
of drug per patient/year, in terms of IU, the 
results for an hypothetical patient with a 
weight of 70 kg are summarized in Figure 1.
As shown above , the use of Kovaltry® as in-
dicated in the SPC (20-40 IU/kg 2-3 times a 







Min Max Mean Min Max Mean Min Max Mean
Kovaltry® (octocog alfa 
from BHK protein free)
20-40 IU/kg 2-3 times 
a week
20 40 30 104 156 130 2,080 6,240 4,160
Advate® (octocog alfa 
from CHO protein free)
20- 40 IU/kg every 2-3 days 20 40 30 122 183 152 2,433 7,300 4,867
Helixate NexGen® 
(octocog alfa from BHK)
20-40 IU/kg every 2-3 days 20 40 30 122 183 152 2,433 7,300 4,867
Refacto AF® 
(moroctocog from CHO 
protein free)
20-40 IU/kg every 2-3 days 20 40 30 122 183 152 2,433 7,300 4,867
Kogenate Bayer® 
(octocog alfa from BHK)
20-40 IU/kg every 2-3 days 20 40 30 122 183 152 2,433 7,300 4,867
Recombinate® (octocog 
alfa from CHO)
20-40 IU/kg every 2-3 days 20 40 30 122 183 152 2,433 7,300 4,867
Nuwiq® (simoctocog 
from HEK protein free)
20-40 IU/kg every 2-3 days 20 40 30 122 183 152 2,433 7,300 4,867
Elocta® (efmoroctocog 
from HEK protein free)
Dose adjustment from 25 
to 65 IU/kg every 3-5 days
25 65 45 73 122 97 1,825 7,908 4,867
Afstyla® (lonoctocog alfa 
from CHO protein free)
20-50 IU/kg 2-3 times a week 20 50 35 104 156 130 2,080 7,800 4,940
NovoEight® (turoctocog 
from CHO protein free)
20-50 IU/kg 3 times a week 20 50 35 156 156 156 3,120 7,800 5,460
20-40 IU/kg every 2 days 20 40 30 183 183 183 3,650 7,300 5,475
table I. Annual average consumption per patient of the available treatments, base on European SPCs [12,15,18-25].
Afstyla®
Afstyla® (lonoctocog alfa, CSL Behring 
SpA), a single chain recombinant human fac-
tor VIII produced in Chinese hamster ovary 
(CHO) cells, is a single polypeptide chain 
with a truncated B-domain that allows for 
a covalent bridge to link the factor VIII he-
avy and light chains [15]. Registrative study 
in adults and adolescent patients determined 
the efficacy and safety in the prevention of 
bleeding events in prophylaxis of Afstyla® 
[16,17]. The study enrolled 175 previously 
treated patients (age: 12 to 65 years) with se-
vere hemophilia A who accumulated a total 
of 14,306 ED with rVIII-SingleChain. A total 
of 146 subjects were assigned to a prophyla-
xis regimen and had a median ABR of 1.14. 
In the study conducted in pediatric popula-
tion on prophylaxis (81 patients, age < 12 ye-
ars), median ABR was 3.69 in both studies no 
patient developed an inhibitor or experienced 
an anaphylactic reaction.
other recombinant products
The other recombinant products for the tre-
atment of hemophilia A currently available 
in Italy, which represent the standard of care, 
are Advate® (octocog alfa from CHO protein 
free, Shire Inc.), Helixate NexGen® e Koge-
nate Bayer® (octocog alfa from BHK, Ba-
yer SpA) Recombinate® (octocog alfa from 
CHO, with human albumin as stabilizer, Shi-
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ces of other rFVIII, we have conservatively 
estimated the average annual cost per patient 
considering the same price per IU (0.65 €) of 
the other rFVIII (excluding Recombinate® 
which has a net selling price of 0.60 €/IU).
As highlighted by the Figure 2, at average do-
sages reported in SPCs [12,15,18-25], all the 
competitors result to be more expensive than 
Kovaltry® on a yearly bases with incremen-
tal costs ranging from about +15,000 €/year 
(+8% for Recombinate®) to +60,000 €/year 
(+32% for NovoEight®). Elocta®, at average 
dosage (45 IU/kg) leads to an incremental 
cost of about € 32,000 (+17%) versus Ko-
valtry®. The last marketed rFVIII, Afstyla® at 
average dosage (35 IU/kg) leads to an incre-
mental cost of about 35,500 € (+19%) versus 
Kovaltry®.
Figura 2. Average annual costs per patient (70 kg weight) for the approved drugs
The potential benefit in terms of drug con-
sumption reduction will be further evaluated 
in real life condition according to current 
clinical practice. As in Italy the rFVIII are 
acquired by NHS facilities through tenders, 
the annual cost was estimated considering the 
average selling prices to NHS structures [26-
38]. As Afstyla® has been very recently reim-
bursed and no data on real selling price (i.e. 
Regional determinations or NHS structures 
tenders) are available, even if approved price 
per IU is higher than the average selling pri-
Figure 1. Annual average drug consumption (IU) for a 70 kg patient (including min-max)
administrations/year without increasing the 
unitary dosage per administration. Conside-
ring average dosages per year of Kovaltry® 
and competitors (reported in SPCs [12,15,18-
25]), all therapies are associated with higher 
drug consumption versus Kovaltry:
 - Standard therapy (Advate®, Helixate 
NexGen®, Recombinate®, Kogenate®, Re-
facto AF®, Nuwiq®) = +17%;
 - Novoeight® = +31%, +32%;
 - Elocta® = +17%;
 - Afstyla® = +19%.
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The estimates of average consumptions and 
related costs of the different rFVIII reported 
in the present analysis, are based on dosages/
frequence of administration reported in the 
European Summary of Product Characteri-
stics and clinical trials and should be confir-
med through real world observations.
However, an approach that has the potential 
to reduces the number of administrations 
per year without any increase in dosage, as 
is proposed for Kovaltry®, can potentially 
improve patient quality of life and faciliate 
compliance to treatment as well as produce 
potential savings for the Italian NHS thanks 
to the reduction of rFVIII utilization and a 
reduction in costs related to a lower risk of 
breakthrough bleedings and the related com-
plications.
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